An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Sapanisertib (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 07 Sep 2017 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
- 07 Sep 2017 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2020.
- 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.